Table 3

Cost effectiveness analysis of a screening programme for asymptomatic Chlamydia trachomatis infections in a low prevalence female population (in US$)

Net cost per woman curedNet cost per MOA
Age group (years)Direct onlyTotalDirect onlyTotal
MOA = major outcome averted (either an episode of PID, chronic pelvic pain, ectopic pregnancy, tubal factor infertility, or neonatal pneumonia).
15–25 802 79211 20011 100
15–401220121016 00015 800